Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease

References

• Rebar R., Judd H. L., Yen S. S. C., Rakoff J., Vandenberg G., Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary disease. J. Clin. Invest. 1976; 57: 1320–9
   Google Scholar
• Yen S. S. C., Vela P., Rankia J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1970; 30: 435–42
   Google Scholar
• Yen S. S. C. The polycystic ovary syndrome. Clin. Endocrinol. 1980; 12: 177–208
   PubMed Web of Science ®Google Scholar
• Cumming D. C., Reid R. L., Quigley M. E., Rebar R. W., Yen S. S. C. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin. Endocrinol. 1984; 20: 643–8
   PubMed Web of Science ®Google Scholar
• Petraglia F., D'Ambrogio G., Comitini G., Facchinetti F., Volpe A., Genazzani A. R. Impairment of opioid control of luteinizing hormone secretion in menstrual disorders. Fertil. Steril. 1985; 43: 534–40
   PubMed Web of Science ®Google Scholar
• Barnes R. B., Mileikowsky G. N., Cha K. Y., Spencer C. A., Lobo R. A. Effects of dopamine and metoclopramide in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1986; 63: 506–9
   Google Scholar
• Falaschi P., Del Pozzo E., Rocco A., Toscano V., Petrangeu E., Pompei P., Frajese G. Prolactin release in polycystic ovary. Obstet. Gynecol. 1980; 55: 579–82
   PubMed Web of Science ®Google Scholar
• Del Pozzo E., Falaschi P. Prolactin and cyclicity in polycystic ovary syndrome. Prog. Re-prod. Biol. 1980; 6: 252–9
   Google Scholar
• Szilàgyi A., Csermely T., Csaba I. Increased prolactin response to TRH in polycystic ovary syndrome with low basal prolactin values. Gynecol. Endocrinol. 1988; 2: 313–17
   PubMed Web of Science ®Google Scholar
• Gjonnaess H., Norman N. Endocrine effects of ovarian electrocautery in patients with polycystic ovarian disease. Br. J. Obstet. Gynaecol. 1987; 94: 779–83
   PubMedGoogle Scholar
• Judd H. L., Riggs L. A., Anderson D. C., Yen S. S. C. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1976; 43: 347–55
   Google Scholar
• Keckstein G., Rossmanith W. G., Schneider V., Spatzier K., Börchers K., Wolf A. S., Steiner R. The effects of laparoscopic treatment of polycystic ovarian disease by CO2-laser or Nd: YAG-laser. Surg. Endosc 1990; 4: 103–7
   PubMed Web of Science ®Google Scholar
• Szilágyi A., Rossmanith W. G., Csermely T., Csaba I. Changes in circulating hormonal levels after ovarian wedge resection in patients with polycystic ovary syndrome. Arch Gynecol. Obstet. 1990; 248: 31–5
   PubMed Web of Science ®Google Scholar
• Rossmanith W. G., Keckstein J., Spatzier K., Lauritzen C. The impact of ovarian laser surgery on the gonadotropin secretion in women with polycystic ovarian disease. Clin. Endocrinol. 1991; 34: 223–30
   PubMed Web of Science ®Google Scholar
• Stein I. F., Cohen M. R. Surgical treatment of bilateral polycystic ovaries, amenorrhea and sterility. Am. J. Obstet. Gynecol. 1939; 38: 465–70
   Google Scholar
• Rossmanith W. G., Wirth U., Benz R., Wolf A. S. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease. Gynecol. Endocrinol. 1989; 3: 21–34
   PubMed Web of Science ®Google Scholar
• Yen S. S. C. Chronic anovulation caused by peripheral endocrine disorders. Reproductive Endocrinology, S. S. C. Yen, R. B. Jaffe. Saunders, New York 1991; 576–630
   Google Scholar
• Grossman A., Moult P. J. A., Gaillard R. C., Delitala G., Toff W. D., Rees L. H., Besser G. M. The opioid control of LH and FSH release: Effects of a met-enkephalin analogue and naloxone. Cline. Endocrinol. 1981; 14: 41–7
   PubMed Web of Science ®Google Scholar
• Rossmanith W. G., Wirth U., Sterzik K., Yen S. S. C. Effects of prolonged opioidergic blockade on LH pulsatile secretion during the menstrual cycle. J. Endocrinol Invest. 1989; 12: 245–53
   PubMed Web of Science ®Google Scholar
• Blankstein J., Reyes F. I., Winter S. D., Faiman C. Endorphins and the regulation of human menstrual cycle. Clin. Endocrinol. 1981; 14: 287–94
   PubMed Web of Science ®Google Scholar
• Petraglia F., Porro C., Facchinetti F., Cicoli C., Bertellini E., Volpe A., Berbieri G. C., Genazzani A. R. Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effects of naloxone but not of morphine. Life Sci. 1986; 38: 2103–10
   PubMed Web of Science ®Google Scholar
• Rossmanith W. G. Endogenous opioid regulation of luteinizing hormone secretion in women. Clinical Perspectives of Opioid Peptide Production, M. Negri, G. Lotti, A. Grossman. Wiley and Sons, London 1992; 164
   Google Scholar
• Barnes R. B., Lobo R. A. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J. Clin. Endocrinol. Metab. 1985; 61: 779–82
   PubMed Web of Science ®Google Scholar
• Berga S. L., Yen S. S. C. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clin. Endocrinol. 1989; 30: 177–84
   PubMed Web of Science ®Google Scholar
• Shoupe D., Lobo R. A. Evidence for altered catecholamine metabolism in polycystic ovary syndrome. Am. J. Obstet. Gynecol. 1984; 150: 566–71
   PubMed Web of Science ®Google Scholar
• Rossmanith W. G., Wirth U., Yen S. S. C. Does prolonged dopaminergic blockade alter the LH pulsatile secretion in normal cycling and postmenopausal women?. Acta Endocrinol. 1989; 121: 147–52
   PubMedGoogle Scholar
• Quigley M. E., Judd S. J., Gilliland G. B., Yen S. S. C. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolac-tinemic anovulation. J. Clin. Endocrinol. Metab. 1979; 48: 718–20
   Google Scholar
• Quigley M. E., Sheehan K. L., Casper R. F., Yen S. S. C. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea. J. Clin. Endocrinol. Metab. 1980; 50: 949–54
   PubMed Web of Science ®Google Scholar
• Alger M., Vasquez-Matute L., Mason M., Canales E. S., Zarate A. Polycystic ovarian disease associated with hyperprolacti-naemia and defective metoclopramide response. Fertil. Steril. 1980; 34: 70–1
   PubMed Web of Science ®Google Scholar
• Buvat J., Buvat-Herbaut M., Marcolin G., Racadot A., Cruplet G., Fossati P. Hyperprolactinemia of polycystic ovary syndrome seems to result from a dopaminergic defeat also acting in elevated serum LH levels. Horm. Res. 1985; 22: 247–53
   Google Scholar
• Yen S. S. C. Studies on the role of dopamine in the control of prolactin and gonadotropin secretion in humans. Central Regulation of the Endocrine System, K. Fuxe, T. Höckfelt, R. Luft. Plenum Press, New York 1979; 387
   Google Scholar